Breast cancer leptomeningeal metastasis—the role of multimodality treatment
The aim of the study was to assess the efficacy of multimodality treatment of patients with Leptomeningeal metastasis (LM) and to establish which method of treatment has the greatest positive impact on survival.
Material and Methods
Clinical material included 67 consecutive breast cancer patients with LM treated at the Cancer Center in Warsaw between the years 2000 and 2005. Intrathecal chemotherapy was given to 57 pts (85%), intravenous chemotherapy to 41 pts (61%), whole brain radiotherapy to 33 pts (49%) and radiotherapy to the spinal leptomeninges to 10 (15%). For 27 pts (40%) three methods of treatment were used. Univariate and multivariate analyses were used to evaluate the impact of the particular method of treatment on survival and to assess the efficacy of combined modalities.
Clinical response was achieved in 49 pts (76%). Median survival calculated from the diagnosis of LM was 16 weeks (range 1–402 weeks). Univariate analysis showed positive impact of systemic intravenous chemotherapy (P = 0,0009), intrathecal chemotherapy (P = 0,008) and whole brain radiotherapy (P = 0,004) on survival. The results of Cox multivariate analysis have shown systemic chemotherapy (P < 0.001) and intrathecal chemotherapy (P = 0.001) to be significant.
Intravenous chemotherapy and, independently, intrathecal chemotherapy improve survival in breast cancer patients with LM. Radiotherapy has a positive impact on the quality of life due to the alleviation of neurological symptoms. The role of radiotherapy in prolonging survival is questionable.
KeywordsBreast cancer Carcinomatous meningitis Chemotherapy Intrathecal therapy Leptomeningeal metastases Radiotherapy
- 2.Steinfeld AD (1999) Radiation therapy. In: Roses DF (ed) Breast cancer, 2nd edn. Churchill Livingstone, PhiladelphiaGoogle Scholar
- 3.Johnson KA, Kramer BS, Crane JM (1998) Management of central nervous system metastases in breast cancer. In: Bland KI, Copeland EM (eds) The breast. Comprehensive management of benign and malignant diseases, 2nd edn. WB Saunders Company, PhiladelphiaGoogle Scholar
- 4.De Angelis LM, Rogers LR, Foley KM (2000) Leptomeningeal metastasis. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the breast, 2nd edn. Lippincott Wiliams &Wilkins, PhiladelphiaGoogle Scholar
- 7.De Angelis L (2004) Leptomeningeal metastasis. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the breast, 3rd edn. Lippincott Williams&Wilkins, PhiladelphiaGoogle Scholar
- 17.Ongerboer de Visser BW, Somers R, Nooyen WH et al (1983) Intraventricular methotrexate therapy of leptomeningeal metastasis from breast cancer. Neurology 33:1565–1572Google Scholar
- 19.Siegal T, Lossos A, Pfeffer MR (1994) Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 4:1463–1469Google Scholar